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ABSTRACT 
Aims:  To assess soluble endothelial cell-specific tyrosine kinase receptor (sTie-2) 
levels in the first trimester of pregnancy and its association with adverse pregnancy 
outcomes; and examine the predictive accuracy. 
Study Design: In this nested case-control study, serum sTie-2 levels were measured 
in 2,616 women with singleton pregnancies attending first trimester screening in New 
South Wales, Australia. Multivariate logistic regression models were used to assess 
the association and predictive accuracy of serum sTie-2 with subsequent adverse 
pregnancy outcomes. 
Results: Median (interquartile range) sTie-2 for the total population was 19.6 ng/ml 
(13.6-26.4). Maternal age, weight, and smoking status significantly affected sTie-2 
levels. There was no difference in serum sTie-2 between unaffected and women with 
adverse pregnancy outcomes. After adjusting maternal and clinical risk factors, low 
sTie-2 (<25
th
 centile) was associated with preeclampsia (Adjusted odds ratio: 1.61; 
95%CI: 1.01-2.57), however, the accuracy of sTie-2 in predicting preeclampsia was 
not different from chance (AUC=0.54; P=0.08) and does not add valuable predictive 
information to maternal and clinical risk factors. 
Conclusions: Our findings suggest that low sTie-2 levels are associated with preeclampsia, 
however, it does not add valuable information to clinical and maternal risk factor 
information in predicting preeclampsia or any other adverse pregnancy outcomes.  
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INTRODUCTION  
 
Endothelial cell-specific tyrosine kinase receptor (Tie-2) is expressed by 
maternal and fetal vascular endothelial cells that mediate several physiological 
functions including placental development
1
. Tie2 receptor signalling controls vascular 
stability and is therefore crucial for angiogenesis and placental growth.  This process 
is enhanced by the presence of other angiogenic factors such as the vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF). Moreover, 
Tie2 signalling on endovascular invasive trophoblasts promotes vascular remodelling 
during pregnancy resulting in the widening of spiral arteries through the loss of 
arterial vascular smooth muscle which is required to establish a high capacity low 
resistance environment to facilitate uteroplacental perfusion
2
.  The tyrosine kinase 
activity of Tie-2 is activated by angiopoietin (Ang)-1which promotes vascular 
stability and maintains cellular contact between endothelial cells and pericytes
3
.  This 
control is antagonized by Ang-2, which binds but does not activate Tie2, through 
competition for the ligand binding site on Tie2.  In the presence of pro-angiogenic 
factors, such as VEGF receptor ligands, this promotes angiogenesis and placental 
formation. 
 
Recent studies have raised the profile of anti-angiogenic agents such as 
soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin as pathogenic 
molecules during gestation. Soluble Flt-1 is an anti-angiogenic factor that may play a 
role in the clinical syndrome of preeclampsia
4
 and other complications such as small 
for gestational age
5
, preterm birth and fetal death
6
. Abnormal high serum levels 
promote poor placentation by sequestering VEGF and PlGF, preventing VEGFR1 
activation on the endothelium and diminishing angiogenesis
7
. Similarly, an alternate 
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path to attenuate Tie-2 signalling on endothelial cells is for the soluble form of Tie2 
receptor (sTie-2) to bind and sequester Ang-1.  Similar to the effects of Ang-2 this 
mechanism prevents the tyrosine kinase activity of full length Tie2 on endothelial 
cells from being activated and deprives cells the stabilising influence of Ang-1. This 
results in the promotion of angiogenesis by other factors to proceed unchecked as well 
as the development of adverse events (such as vascular permeability and tissue 
oedema, inflammation of the vessel wall and often endothelial cell dysfunction).  The 
extracellular domain of Tie2 is released into the circulation by a shedding mechanism, 
similar to the soluble form of the VEGF receptor-1, and may participate in the 
regulation of angiogenesis by binding to free Ang-1 and Ang-2
8
. 
 
Many of these processes feature in pathological pregnancies. We have 
previously reported an association between low first trimester serum levels of Ang-2 
with the subsequent development of preeclampsia, small for gestational age infant, 
preterm birth and miscarriage
9
. We hypothesise that the Ang-2/Tie-2 binding 
mechanism would be altered in compromised pregnancies and therefore be expressed 
in abnormal first trimester sTie-2 serum levels. Previous studies have reported no 
association between serum sTie-2 levels in first and second trimester 
10
 and decreased 
serum sTie-2 levels at term in women with preeclampsia or that had a SGA infant 
11,12
. However, these studies were small, not representative of a general maternity 
population and inadequate to determine normative levels in pregnancy. Additionally, 
there is no information about plausible valuable predictive information of first 
trimester sTie-2 added to risks assessment that can be determined from an antenatal 
booking history.  Identification of women at risk of developing adverse pregnancy 
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outcomes early in pregnancy would allow ample time for monitoring and 
implementing preventive strategies. 
 
There were three aims of this study: (i) to determine normative serum levels of 
soluble Tie2 in the first trimester of pregnancy; (ii) assess the association of maternal 
serum soluble Tie2 in first trimester with the risk of adverse pregnancy outcomes; and 
(iii) to assess the clinical utility of sTie2 in the prediction of adverse pregnancy 
outcomes. 
 
METHODS 
Study population and sample testing 
This case-cohort study was conducted from a cohort of 11,130 women 
attending first trimester Down syndrome screening between January and October 
2007 in New South Wales (NSW), Australia. Serum samples were collected by the 
Pacific Laboratory Medicine Services (PaLMs), and then archived and stored at -
80°C. During this period, this was the state’s only public screening service and 
received samples from throughout NSW. 
 
Serum samples for this study were thawed and serum levels of sTie-2 
measured using a Quantikine ELISA immunoassay (R&D Systems, Minneapolis, 
MN). The reported analytic sensitivity of the immunoassays was 0.156 – 10.00 ng/ml 
and the intra-assay and inter-assay coefficient of variation were <17%. Serum samples 
were routinely diluted 1 in 10 prior to measurement. Serum samples were stored 
according to time of collection in boxes containing 81 samples in 9x9 rows. Cases of 
each study outcome of interest (small for gestational age (SGA), preterm birth, 
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preeclampsia, gestational diabetes, miscarriage and stillbirth) were selected using a 
computerized random-number function, with the specific box and row identified. 
Laboratory scientists then located and analysed the full row of the storage box (9 
samples) containing the case but were unaware its position within the row. The 
remaining eight samples in each row were used as controls, regardless of their 
outcome status. Inevitably, the pregnancy outcome for some of these eight samples 
was subsequently identified to be pregnancy complications and these were allocated 
to the relevant case status, accordingly. This allowed laboratory scientists to remain 
blinded to pregnancy outcomes and increase the efficiency of processing. 
 
Data sources 
Maternal information for archived serum samples was derived from the 
laboratory database and corresponding pregnancy and birth outcomes were 
ascertained via record linkage from the Perinatal Data Collection (PDC) and the 
Admitted Patient Data Collection (APDC). The PDC includes records of all births in 
NSW of at least 400 grams birth weight, or at least 20 weeks’ gestation and includes 
demographic, medical and obstetric information on the mother, labour, delivery and 
birth outcome.  The APDC includes records for both mothers and liveborn infants 
from hospital admissions in NSW public and private hospitals. It contains 
demographic, clinical and health services information for each admission. Relevant 
diagnoses and procedures are recorded for each hospital admission and coded 
according to the International Classification of Diseases version 10 – Australian 
Modification (ICD10-AM) and Australian Classification of Healthcare Interventions, 
respectively. In Australia unique identifiers are not available for record linkage of unit 
record data from multiple datasets 
13
. Consequently probabilistic linkage methods 
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were utilised. This involves a complex process of blocking and matching 
combinations of personal identifiers (such as name, date of birth, address and 
hospital) using record-linkage software
14
. Probability weights are calculated, adjusted 
for incomplete and missing data, and used to establish correct matches. The validity 
of the probabilistic record linkage is extremely high with less than 1% of records 
having an incorrect match
13-16
. The NSW Centre for Health Record Linkage 
conducted the record linkage and identifying information was removed prior to the 
release of data for analysis. The CHeReL assesses the linkage quality for each study, 
and for this study reported <5/1000 missed links and <2/1000 false positive links. The 
study was approved by the NSW Population and Health Services Research Ethics 
Committee. 
Study outcomes assessed included: small for gestational age (SGA), preterm 
birth, preeclampsia, gestational diabetes, miscarriage and stillbirth. SGA was defined 
as birthweight less than the 10
th
 centile and less than the 3
rd
 centile (severe SGA) of 
the distribution for gestational age and infant sex 
17
. Gestational age is reported in the 
birth data in completed weeks of gestation and determined by the best clinical 
estimate including early ultrasound (>97%) and last menstrual period. Preterm birth 
was defined as delivery at less than 37 weeks and very preterm birth less than 34 
weeks gestation. During the study period, preeclampsia was defined as onset of 
hypertension (systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 
mmHg) from 20 weeks’ gestation accompanied by proteinuria 18. Information on 
preeclampsia was obtained from both the APDC and PDC data, to maximize 
ascertainment
19,20
. Early onset preeclampsia was defined as women with preeclampsia 
delivered at ≤34 weeks gestation. Miscarriage was defined as a spontaneous 
pregnancy loss between 10-20 weeks gestation and identified from APDC data, while 
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stillbirth was defined as a spontaneous pregnancy loss after 20 weeks gestation and 
was identified from PDC data.  
 
The key explanatory variable for this study was sTie-2. Information on serum 
Ang-1 and Ang-2 concentrations were available for 1,058 women and were obtained 
from data from a previous study
9
. Additional covariate information available for the 
analysis included maternal age and weight (kilograms) ascertained at the time of first 
trimester screening, parity (nulliparous/multiparous), smoking during pregnancy, 
previously diagnosed hypertension (chronic or pregnancy), previously diagnosed 
diabetes (pre gestational or gestational), previous miscarriage, country of birth and 
socio-economic disadvantage. Socio-economic disadvantage was defined according to 
the Socio-Economic Indexes for Areas (SEIFA) relative disadvantage scores 
developed by the Australian Bureau of Statistics (ABS) 
21
 and categorized into 
quintiles. Maternal weight was missing in 380 (14.5%) of the records and multiple 
imputation was used to substitute this 22. Other missing data were infrequent and were 
excluded from the analyses: smoking was missing in 24 (1.2%) and country of birth in 
3 (0.1%) of the records. 
 
Statistical analysis 
As the study population was selected from a population based-cohort, we 
weighted sTie-2 to account for sampling probabilities to determine normative 
concentrations for a pregnancy cohort. Weight calculation involved multiplying each 
case and control by the inverse proportion of the probability of selection. The sTie-2 
distribution was then calculated applying individual weights. Similarly, to ensure 
comparability with the NSW state maternity population, we weighted all observations 
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for the population rates of age, parity, smoking and socio-economic disadvantage 
using SEIFA quintiles 
23
. Descriptive statistics were calculated and spearman 
coefficient was used to determine the correlation between sTie-2, Ang-1 and Ang-2 
after logarithmic transformation. Kruskall-Wallis test was used to compare 
concentrations of sTie-2 by maternal characteristics and between women that 
subsequently had an adverse pregnancy outcome with women with unaffected 
pregnancies. Multiple of the Medians (MoM) were calculated for sTie-2, Ang-1 and 
Ang-2 levels, to account for differences in values attributable to gestational week of 
the test, maternal age or maternal weight.  Soluble Tie-2 MoM levels were then 
dichotomized by the <25
th
 and the >75
th
 centile.  
 
Conditional multivariate logistic regression was used to assess the association 
between low and high sTie-2 MoM with adverse pregnancy outcomes, taking into 
account maternal and clinical risk factors. A backward elimination method retaining 
only significant explanatory variables was used to fit models for each outcome. We 
then assessed the predictive accuracy of sTie-2 by examining the area under the 
Receiver Operating Characteristic (ROC) curve (AUC), derived from logistic 
regression analysis.  AUC results were also examined to determine whether models 
performed better than chance (0.5). Models for serum sTie-2 alone, those including 
maternal and clinical risk factors only and with sTie-2 and risk factors combined were 
compared. This method was applied to assess whether serum levels of sTie-2 
provided any additional information to maternal and clinical risk factors in predicting 
severe adverse pregnancy outcomes by evaluating the maximum likelihood estimates 
using the likelihood ratio (X
2
) test. A P-value of <0.05 was considered statistically 
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significant and analyses were performed using SAS software 9.3 (SAS Institute Inc., 
Cary, NC, USA).  
 
RESULTS 
A total of 2,987 samples were tested with health information of the relevant 
pregnancy available for 2,774 (92.9%) samples. Excluded were 179 women whose 
blood sample were taken before 10 or after 14 weeks gestation, had a twin pregnancy, 
a medical abortion, or an infant with a major congenital anomaly. Soluble Tie-2 was 
undetectable in 240 samples and these women were assigned a value equal to half the 
limit of detection 
24
. A total of 2,595 women were included in the analysis. The mean 
(SD) maternal age and weight were 32.9 (4.9) years and 66.8 (14.9) kilos, 
respectively. 1,261 (48.2%) women where nulliparous, 167 (6.4%) smoked during 
pregnancy and 136 (5.2%) women had previously diagnosed hypertension. Table 1 
presents the median interquartile range (IQR) serum levels of sTie-2 by maternal 
characteristics. The median (IQR) serum levels of sTie-2 for total population of were 
9.0 ng/ml (3.3 – 14.7). Compared with women that did not smoke (median 8.5 ng/ml; 
IQR: 2.8 - 14.2), median sTie-2 was higher in women who smoked during pregnancy 
(median 12.2 ng/ml IQR: 7.2 – 16.1). Serum Tie-2 concentrations were also higher 
among women <25 years and weight >85 kilograms, but lower among women aged 
over 40 years. Serum sTie-2 increased with increasing maternal weight (r =0.09, 
P<0.001) and decreased with increasing maternal age (r = -0.08, P<0.001) (Table 1). 
Levels of sTie-2 did not change by gestational age between 10 and 14 weeks. No 
correlation between sTie-2 with Ang-1 (r = -0.008; P=0.79) or Ang-2 (r = -0.031; 
P=0.31), was observed. 
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Figure 1 presents median (IQR) serum levels of serum sTie-2 by adverse 
pregnancy outcome. There was no difference in sTie-2 levels between unaffected 
women with woman who subsequently developed adverse pregnancy outcomes. The 
association of low sTie-2 MoM (<25
th
 centile) and high sTie-2 MoM (>75
th
 centile) 
with adverse pregnancy outcomes is presented in Table 2. Low sTie-2 (<0.31 MoM) 
was associated with 60% increased risk of preeclampsia. There was a tendency for 
women with low Tie-2 to be at increased risk of early onset preeclampsia or 
miscarriage and high sTie-2 of stillbirth, but these associations did not reach statistical 
significance due to small number of cases.  
 
Figure 2 illustrates the receiver operating characteristic curves (ROC) of sTie-
2 in predicting preeclampsia, early-onset preeclampsia miscarriage and stillbirth in 
comparison with maternal and clinical risk factors. The predictive accuracy of low or 
high sTie-2 alone was not different from chance for preeclampsia (AUC=0.54; 
P=0.08), early-onset preeclampsia (AUC=0.65; P=0.08), miscarriage (AUC=0.58; 
P=0.15) and stillbirth (AUC=0.58; P=0.18). Sensitivity, specificity and positive 
likelihood ratios were: for preeclampsia (33%, 75% and 1.32), early-onset 
preeclampsia (44%, 75% and 1.75), miscarriage (41%, 75% and 1.62) and for 
stillbirth (40%, 75% and 1.61), respectively. Maternal risk factors alone had better 
predictive accuracy compared with sTie-2 and adding sTie-2 to maternal risk factors 
did not improve the ability of the models to predict preeclampsia (X
2
=1.12; P=0.29), 
early-onset preeclampsia (X
2
=0.57; P=0.45), miscarriage (X
2
=0.63; P=0.42) and 
stillbirth (X
2
=0.53; P=0.46) (Figure 2).  
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DISCUSSION 
This the largest population-based study to examine maternal soluble Tie-2 
levels of women in first trimester, and assessed the association with adverse 
pregnancy outcomes. This is also the first study evaluating the predictive accuracy of 
serum sTie-2 in first trimester. Our study highlights that serum sTie-2 concentrations 
in pregnant women are affected by maternal age, weight and smoking. There was no 
difference in median sTie-2 between women who developed adverse pregnancy 
outcomes and those who did not. After adjusting for maternal and clinical risk factors, 
low first trimester sTie-2 in first trimester was associated with preeclampsia, however, 
it did not predict preeclampsia or any other adverse pregnancy outcome better than 
maternal and clinical risk factors. 
 
Variation in serum sTie-2 by age and smoking has been reported in both 
pregnant and non-pregnant populations
10,25
.  While weight has been reported to 
influence sTie-2 concentrations in non-pregnant populations
25
, no correlation has been 
found between sTie-2 concentrations with BMI in pregnant women 
10
.  Adipose 
tissue, a highly vascular and active endocrine organ, may be a source of angiopoietins 
and their receptors; and may influence sTie-2 levels 
26
. Despite variation by maternal 
characteristics, previous studies have also described constant serum sTie-2 levels 
across first trimester 
27
, mid pregnancy 
10
 and a slight increase after 26 weeks 
gestation 
12
. 
 
Although there have been a number of studies examining sTie-2 in pregnancy. 
only two assessed sTie-2 in first trimester and the association with adverse pregnancy 
outcomes
10,28
. Our findings are consistent with these studies that reported no 
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difference in first trimester sTie-2 levels in women subsequently diagnosed with 
preeclampsia or had an infant diagnosed with IUGR, compared with unaffected 
women.   
 
Soluble Tie2 is functional, binding both Ang1 and Ang2, and inhibits ligand-
mediated receptor activation and downstream cellular responses
29
. Furthermore, 
abnormal sTie-2 levels are associated with other pathologies involving vascular 
remodelling, such as acute coronary syndromes
30
.  Overall, our results indicate that 
impairment of placental angiogenesis may not be substantial enough to alter serum 
sTie-2 levels, at least in first trimester, to predict subsequent development of 
preeclampsia. Although we found a borderline association between low sTie-2 with 
preeclampsia, these may be chance findings and further studies and larger cases 
numbers are required to confirm these findings and the tendency towards increased 
odds of early-onset preeclampsia, miscarriage or stillbirth.  These associations may 
suggest the role of angiogenic/anti-angiogenic factors in the pathogenesis of adverse 
pregnancy outcomes, however, their value in screening of women at-risk of these 
conditions may be not appropriate in a clinical setting. In a recent study, we found 
that despite a positive association between elevated first trimester Ang-1/Ang-2 ratio 
levels with SGA, preeclampsia, preterm birth and miscarriage in a large cohort of 
women
9
, the overall predictive accuracy was poor. 
 
Studies evaluating serum angiogenic/anti-angiogenic factors such as placental 
growth factor and soluble vascular endothelial growth factor receptor-1, have 
provided promising results for the diagnosis
4
, prognosis
31
, and assessment of severity 
of adverse pregnancy outcomes
32
. But this evaluation has focused later in pregnancy, 
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when it may be too late for preventive interventions to be effective. Early pregnancy 
assessment provides an ideal opportunity to incorporate an additional test into 
existing, routine antenatal testing for identification of pregnancies at-risk of adverse 
pregnancy outcomes for closer surveillance. To date, first trimester serum levels of 
agiogenic/anti-angiogenic biomarkers, single or combined, have not provided 
adequate predictive accuracy for antenatal screening. Moreover, in a previous study 
we found that compared with serum biomarker information alone, routinely collected 
maternal and clinical risk factors, such as parity, previously diagnosed hypertension 
and maternal weight provide better accuracy in 
predicting preeclampsia
33
. 
 
Strengths of the study were the evaluation of a large sample from a 
population-based cohort of pregnant women attending first trimester screening. 
Ascertainment and follow-up of pregnancy outcomes was possible for 92% of the 
samples using record linkage of laboratory to birth and hospital data with only 
minimal missing information. Missing health and pregnancy information was mostly 
attributable to women giving birth in hospitals out of state. Yet, women with missing 
information had similar characteristics compared with those included in the study. 
One of the limitations of the study was that maternal weight was missing in 14.5% of 
the women, which was addressed by applying multiple imputations, a technique 
shown to be robust and valid for dealing with missing data 
22
. Our results for 
miscarriage must be interpreted with caution as miscarriage is under ascertained. 
First, it was restricted to women screened from 10 to 14 weeks and second, only 
miscarriages resulting in admission to hospital can be identified. Another potential 
weakness were the socio-demographic differences between our cohort compared with 
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the total state maternity population during the same period, which may be due to a 
healthier and more affluent group attending first trimester screening. We addressed 
this issue by weighting our data by population characteristics to ensure 
generalizability of the results.  
 
In conclusion, our findings suggest that low sTie-2 concentrations in first trimester 
are associated with subsequent onset of preeclampsia, but do not predict preeclampsia or 
other adverse pregnancy outcomes any better than clinical and maternal risk factor 
information.  
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Table 1: First trimester soluble Tie-2 serum levels by maternal characteristics   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IQR: Interquartile range; NA: North America; SA: South Africa  
 
 
 
 
 
 
 
Maternal characteristics 
  sTie-2 (ng/ml)   
n (%) Median (IQR) P-value 
All women 2595 9.0 (3.3, 14.7) 
 
Maternal age 
   
<25 162 (6.2) 11.6 (4.9, 15.6) 0.01 
25 - 29 532 (20.3) 9.9 (4.0, 15.2) 
 
30 - 34 983 (37.6) 8.3 (2.8, 13.7) 
 
35 - 39 789 (30.2) 8.4 (2.4, 14.2) 
 
40+ 150 (5.7) 7.7 (2.5, 14.7) 
 
Parity 
   
Nulliparous 1261 (48.2) 8.7 (3.1, 14.0) 0.13 
Parous 1355 (51.8) 9.4 (3.6, 15.1) 
 
Smoking during 
pregnancy    
Yes 167 (6.4) 12.2 (7.2, 16.1) <0.001 
No 2425 (93.6) 8.5 (2.8, 14.2) 
 
Maternal weight (kg) 
   
<55 428 (19.1) 8.5 (4.2, 13.5) <0.001 
55 - 64 452 (20.2) 7.4 (1.9, 14.0) 
 
65 - 74 403 (18.0) 8.1 (2.7, 13.0) 
 
75 - 84 484 (21.7) 9.1 (3.2, 15.4) 
 
85+ 469 (21.0) 11.4 (5.5, 15.9) 
 
Gestational week at 
sampling    
10 256 (9.8) 10.2 (3.0, 14.2) 0.08 
11 846 (32.3) 8.2 (2.7, 14.3) 
 
12 1072 (41.0) 9.5 (3.8, 15.2) 
 
13 442 (16.9) 8.8 (4.6, 14.5) 
 
Country of birth 
   
Australia & New Zealand 1683 (64.4) 9.2 (3.5, 14.8) 0.47 
Pacific Islands 25 (1.0) 7.3 (3.3, 12.5) 
 
Europe, NA & SA 255 (9.8) 7.7 (2.0, 14.4) 
 
Middle east 63 (2.4) 10.6 (2.5, 15.0) 
 
South east Asia 176 (6.7) 9.2 (4.6, 13.6) 
 
China, Hong Kong & 
Taiwan 
162 (6.2) 10.8 (4.6, 15.0) 
 
Japan and Koreas 70 (2.7) 8.8 (4.4, 15.0) 
 
India & surroundings 115 (4.4) 7.5 (1.6, 14.2) 
 
Central and South 
America 
39 (1.5) 3.1 (1.5, 11.1) 
 
Africa and Caribbean 24 (0.9) 6.8 (2.0, 16.2) 
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Figure 1: First trimester serum soluble Tie-2 levels in women that subsequently 
developed adverse pregnancy outcomes compared with unaffected women. The line 
inside the boxes represents the median value and diamond represents the mean.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.35 P=0.09 P=0.56 P=0.71 P=0.29 
Table 2: Association of first trimester Tie-2 with adverse pregnancy outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adjusted for: maternal age, parity, smoking during pregnancy, maternal weight, previously diagnosed hypertension, previously diagnosed diabetes,  
country of birth or socio-economic disadvantage. a Reference  sTie2 MoM: 0.31 – 1.68.  
 
 
 
 
     Univariate Odds ratio (95% CI)  Adjusted Odds ratio (95% CI)*  
Pregnancy 
outcome 
Affected 
with low 
sTie-2 
Affected 
with 
high sTie-2 
Low sTie-2        
MoM <0.31
a
 
High sTie-2  
MoM >1.68
 a
 
Low sTie-2      
MoM <0.31
 a
 
High sTie-2    
MoM >1.68
 a
 
SGA<10th centile 
(n=298)                    
78 75  1.07 (0.80, 1.44)  1.04 (0.77, 1.40)  1.11 (0.82, 1.49)  1.06 (0.78, 1.44) 
SGA<3rd centile 
(n=73) 
20 18  1.13 (0.65, 1.98)  1.03 (0.58, 1.84) 1.27 (0.72, 2.24) 1.11 (0.62, 2.00) 
Preterm birth <37 
weeks (n=196) 
45 55 0.94 (0.65, 1.36) 1.18 (0.83, 1.67) 0.97 (0.68, 1.40) 1.22 (0.86, 1.73) 
Preterm birth <34 
weeks (n=68) 
18 20  1.19 (0.66, 2.15)  1.33 (0.75, 2.37)  1.24 (0.68, 2.25)  1.32 (0.73, 2.37) 
All preeclampsia 
(n=110) 
35 24 1.48 (0.95, 2.32) 1.02 (0.62, 1.68) 1.61 (1.01, 2.57) 1.13 (0.67, 1.92) 
Early-onset 
preeclampsia (n=9) 
4 3 3.93 (0.72, 21.48) 2.99 (0.50, 17.93)  4.13 (0.75, 22.79)  2.68 (0.43, 16.57) 
Miscarriage (n=22) 9 4 1.97 (0.78, 4.98) 0.88 (0.27, 2.88)  2.08 (0.82, 5.28)  0.96 (0.29, 3.14) 
Stillbirth  (n=20) 5 8  1.40 (0.44, 4.43)  2.29 (0.83, 6.34) 1.48 (0.47, 4.70) 2.49 (0.89, 6.97) 
Figure 2: Receiver Operating Characteristic curves comparing first trimester serum 
Tie-2 with maternal and clinical risk factors predicting preeclampsia, early onset 
preeclampsia, miscarriage and stillbirth. AUC: Area under the curve. Risk factors are: 
maternal age, parity, smoking during pregnancy, maternal weight, previously 
diagnosed hypertension, previously diagnosed diabetes, country of birth or socio-
economic disadvantage. 
 
